Former OpenAI science lead launches Warp Science to automate wet labs with robots
The new startup raised a $215 million round led by Lightspeed.
标签：biotech
共 32 篇相关文章
OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, an…
Khosla Ventures doubles down on Even Healthcare to challenge India’s hospital economics
Even Healthcare reaches a $300 million valuation in a Khosla Ventures-led round as it plans to expand its hospital netwo…
Mark Wahlberg wants to take on the longevity-startup crowd with an affordable gym concept
Mark Wahlberg, who once sank money into a gym chain that got kicked off the NYSE, is now building his own, and he promis…
TechCrunch Disrupt 2026: Last day
Last day to join TechCrunch Disrupt 2026. Join 10,000+ tech leaders for a day of connections and insights. Save 75% on y…
Intero Biosystems wants drugmakers to test on mini human intestines, not animals
Intero Biosystems is selling lab-grown human intestines to drugmakers as regulators push for alternatives to animal test…
Colossal Biosciences announces new AI platform to help accelerate de-extinction efforts
Colossal announced a new AI platform to help accelerate its de-extinction efforts and Peter Diamandis has launched a new…
TimeTeller puts our internal clocks at the center of personalized medicine
German startup TimeTeller has developed a saliva test kit to help anyone understand their circadian rhythm; it aims to r…
Mosqitter is turning its mosquito traps into an AI-powered surveillance network
Mosqitter is turning its mosquito-trapping hardware into an AI-powered surveillance network designed to identify species…
Save 50% on your TechCrunch Disrupt 2026 ticket and join the last two days in San Francisco’s Moscone West
Get 50% discount on the last two days of TechCrunch Disrupt 2026, Oct. 14-25, in San Francisco's Moscone West. Register …
TechCrunch Disrupt 2026: Day 2
Day 2 at TechCrunch Disrupt 2026, full of all themes across AI, investor-only session, more roundtables, and more. Regis…
当退货成为BD交易新常态，Biotech何去何从？
CGT商业化难背景下的无奈之举。